Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Tempest Therapeutics, Inc.
organization5 mentionslast seen Nov 12, 2026
A Delaware corporation that entered into a securities purchase agreement for a private placement of pre-funded warrants and common warrants.
Relationships 12
- Tempest Therapeutics, Inc.employsMatthew Angel99% confidence5 sources
- Tempest Therapeutics, Inc.developsin vivo CAR-T therapy99% confidence2 sources
- Tempest Therapeutics, Inc.developsTPST-400399% confidence2 sources
- Tempest Therapeutics, Inc.partners withHebei Senlang Biotechnology Co., Ltd.99% confidence2 sources
- Tempest Therapeutics, Inc.acquiresCD7-targeted lentiviral vector platform95% confidence1 source
- Tempest Therapeutics, Inc.funded byTempest Therapeutics Private Placement95% confidence1 source
- Tempest Therapeutics, Inc.developslipid nanoparticle in vivo CAR-T delivery platform93% confidence1 source
- Tempest Therapeutics, Inc.developsTPST-490393% confidence1 source
- Tempest Therapeutics, Inc.suppliesFactor Bioscience Inc.92% confidence1 source
- H.C. Wainwright & Co.suppliesTempest Therapeutics, Inc.90% confidence1 source
- Tempest Therapeutics, Inc.partners withFactor Bioscience Inc.88% confidence1 source
- Tempest Therapeutics, Inc.employsNancy Freda-Smith85% confidence1 source
Relationship
Tempest Therapeutics, Inc.employsMatthew Angel
99% confidence5 supporting mentions
Either name opens that entity’s relationships.
Sources 5
- filingSEC EDGARNov 12, 2026Tempest Therapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Matthew Angel Title: President and Chief Executive Officer
- filingSEC EDGAROct 20, 2026Tempest Therapeutics, Inc. 8-K: Item 5.07: Submission of Matters to a Vote of Security Holders; Item 8.01: Other Events
Matthew Angel Name: Matthew Angel Title: President and Chief Executive Officer
- filingSEC EDGARSep 28, 2026Tempest Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Dr. Matt Angel, Ph.D., Tempest's President and Chief Executive Officer and a member of its Board of Directors
- filingSEC EDGARSep 17, 2026Tempest Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
- filingSEC EDGARSep 15, 2026Tempest Therapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 9.01: Financial Statements and Exhibits
Matthew Angel President and Chief Executive Officer